Ardsley Advisory Partners LP Has $7.69 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Ardsley Advisory Partners LP increased its stake in Teva Pharmaceutical Industries by 66.7%, owning a total of 500,000 shares valued at approximately $7.7 million.
• Teva's stock price increased by 2.2%, with a current price of $18.79, and it has a market capitalization of $21.55 billion.
• Analysts have upgraded Teva's stock ratings, with targets ranging from $20.00 to $25.00, indicating a positive outlook on the company's growth potential.

Ardsley Advisory Partners LP lifted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 66.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 500,000 shares of the company's stock after purchasing an additional 200,000 shares during the quarter. Teva Pharmaceutical Industries accounts for about 1.5% of Ardsley Advisory Partners LP's investment portfolio, making the stock its 19th largest holding. Ardsley Advisory Partners LP's holdings in Teva Pharmaceutical Industries were worth $7,685,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of TEVA. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $39,000. New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $54,000. Banque Cantonale Vaudoise acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $74,000. Finally, Brooklyn Investment Group boosted its position in shares of Teva Pharmaceutical Industries by 403.4% in the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock valued at $77,000 after purchasing an additional 4,014 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.49% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TEVA. Truist Financial began coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective for the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Finally, UBS Group cut their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded up $0.46 during trading on Friday, reaching $18.94. The company had a trading volume of 7,802,703 shares, compared to its average volume of 9,725,214. The firm's 50 day simple moving average is $17.04 and its two-hundred day simple moving average is $16.40. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The company has a market capitalization of $21.72 billion, a PE ratio of -118.35, a PEG ratio of 1.12 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's revenue was up .3% compared to the same quarter last year. During the same period last year, the business earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.